D. Ramone

O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Shin-ichiro Takahashi, A. Oaknin, D. Lorusso, 2021, Oral Abstracts.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2022, Annals of Oncology.

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2021, Annals of Oncology.